G1 Therapeutics Halts Phase 3 Breast Cancer Drug Trial As Data Disappoints
G1 Therapeutics Halts Phase 3 Breast Cancer Drug Trial As Data Disappoints
g1 therapeutics因數據不理想而暫停第三期乳腺癌藥物試驗
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊